PubMed:32338224 / 9766-9939 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T290","span":{"begin":7,"end":20},"obj":"CHEBI:52217"},{"id":"T291","span":{"begin":7,"end":20},"obj":"CHEBI:52217"},{"id":"T292","span":{"begin":76,"end":80},"obj":"G_3"},{"id":"T293","span":{"begin":76,"end":80},"obj":"PG_10"},{"id":"T294","span":{"begin":76,"end":80},"obj":"PR:000003622"},{"id":"T295","span":{"begin":106,"end":117},"obj":"UBERON:0001004"},{"id":"T296","span":{"begin":131,"end":142},"obj":"UBERON:0002349"},{"id":"T297","span":{"begin":146,"end":154},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"From a pharmacologic point of view, RAS inhibition leads to upregulation of ACE2, thus, attenuating acute respiratory syndrome and myocarditis in COVID-19-infected patients."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T24","span":{"begin":36,"end":39},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"From a pharmacologic point of view, RAS inhibition leads to upregulation of ACE2, thus, attenuating acute respiratory syndrome and myocarditis in COVID-19-infected patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T57","span":{"begin":131,"end":142},"obj":"Disease"},{"id":"T58","span":{"begin":146,"end":154},"obj":"Disease"}],"attributes":[{"id":"A57","pred":"mondo_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/MONDO_0004496"},{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"From a pharmacologic point of view, RAS inhibition leads to upregulation of ACE2, thus, attenuating acute respiratory syndrome and myocarditis in COVID-19-infected patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T131","span":{"begin":5,"end":6},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"From a pharmacologic point of view, RAS inhibition leads to upregulation of ACE2, thus, attenuating acute respiratory syndrome and myocarditis in COVID-19-infected patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T62","span":{"begin":36,"end":39},"obj":"Chemical"}],"attributes":[{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"}],"text":"From a pharmacologic point of view, RAS inhibition leads to upregulation of ACE2, thus, attenuating acute respiratory syndrome and myocarditis in COVID-19-infected patients."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T13","span":{"begin":131,"end":142},"obj":"Phenotype"}],"attributes":[{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0012819"}],"text":"From a pharmacologic point of view, RAS inhibition leads to upregulation of ACE2, thus, attenuating acute respiratory syndrome and myocarditis in COVID-19-infected patients."}

{"project":"PubMed_ArguminSci","denotations":[{"id":"T60","span":{"begin":0,"end":173},"obj":"DRI_Challenge"}],"text":"From a pharmacologic point of view, RAS inhibition leads to upregulation of ACE2, thus, attenuating acute respiratory syndrome and myocarditis in COVID-19-infected patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T60","span":{"begin":0,"end":173},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"From a pharmacologic point of view, RAS inhibition leads to upregulation of ACE2, thus, attenuating acute respiratory syndrome and myocarditis in COVID-19-infected patients."}